A COMPARATIVE STUDY OF OLOPATADINE 0.01% COMBINED FLUOROMETHOLONE 0.1% TREATMENT VERSUS OLOPATADINE 0.01% COMBINED KETOROLAC 0.4% TREATMENT IN ALLERGIC CONJUNCTIVITIS IN SAROJINI DEVI EYE HOSPITAL

N. KARUNA SREE; KHATIJATUL KUBRA NAMEERA; THOMAS SANGA; FAHEEM BEGUM; V. NAVYA; NABEELA FATIMA

doi:10.22159/ijpps.2023v15i10.47483

Authors

N. KARUNA SREE Department of Pharmacology, Osmania Medical College, Hyderabad-500007, India
KHATIJATUL KUBRA NAMEERA Department of Pharmacology, Osmania Medical College, Hyderabad-500007, India
THOMAS SANGA Department of Pharmacology, Osmania Medical College, Hyderabad-500007, India
FAHEEM BEGUM Department of Pharmacology, Osmania Medical College, Hyderabad-500007, India
V. NAVYA Department of Pharmacology, Osmania Medical College, Hyderabad-500007, India
NABEELA FATIMA St Pauls College of Pharmacy, Turkayamjal (V), Nagarjuna Sagar Road, R. R. Dist, Hyderabad-501510, India

DOI:

https://doi.org/10.22159/ijpps.2023v15i10.47483

Keywords:

Allergic conjunctivitis, Olapatadine, Fluorometholone, Ketorolac

Abstract

Objective: Comparative study of the efficacy of olopatadine 0.01% combined fluorometholone 0.1% treatment versus olopatadine 0.01% combined ketorolac 0.4% in the treatment of Allergic Conjuctivitis.

Methods: This was a randomized control trial done on 80 subjects with 40 subjects in each group. The clinical signs (chemosis, mucus secretion, eyelid edema) and symptoms (itching, redness, watery eyes, burning) of the patients were evaluated by summing up the scores using a 3-point scale at baseline,1^st and 7^th day of initiation of treatment. Results were analyzed by Student’s Independent t-test to assess the significant difference of means between the groups. p-value less than 0.05 was considered significant.

Results: The mean age of the study subjects was 29.8±13.5 in Group A and 32.6±8.8 in Group B. Majority were females in both group A and group B with 52.5% and 62.5% respectively. The reduction was high for chemosis (87.7%) followed by mucous secretion (87.5%) in group A. Highest reduction was seen with itching (59.9%) followed by burning (52.5%) in group B. Significant difference between the groups was noticed with itching (p=0.04), mucous secretion(p=<0.001), chemosis (p=0.01) and eyelid oedema (p=0.009). No significant difference was observed between the two groups (p=0.15) regarding adverse events.

Conclusion: Olopatadine 0.01% combined fluorometholone 0.1% had better efficacy than olopatadine 0.01% combined ketorolac 0.4%.

Downloads

Download data is not yet available.

References

Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study-PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/20383847. [Last accessed on 25 Jan 2023]

Evidence-based study design in ocular allergy trials-PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/18769206. [Last accessed on 25 Jan 2023]

Allergic conjunctivitis: update on pathophysiology and prospects for future treatment-PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/15637556 [Last accessed on 25 Jan 2023]

The epidemiology of ocular and nasal allergy in the United States; 1988-1994-. PubMed. Available from: https://pubmed.ncbi.nlm. [Last accessed on 25 Jan 2023]

Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis-Yaylali-2003-Acta Ophthalmologica Scandinavica-Wiley Online Library. Available from: https://onlinelibrary.x?sid=nlm%3Apubmed#b1.wiley.com. doi: 10.1034/j.1600-0420.2003.00079. [Last accessed on 25 Jan 2023]

Allergic conjunctivitis; 2021. Available from: https://www.hopkinsmedicine.org/health/conditions-and-diseases/allergic-conjunctivitis. [Last accessed on 25 Jan 2023]

Clinical implications of mast cell involvement in allergic conjunctivitis-Elieh Ali Komi-2018-Allergy-Wiley Online Library. Available from: https://onlinelibrary.wiley.com. [Last accessed on 25 Jan 2023]

Red-eye Press-PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/10922425. [Last accessed on 25 Jan 2023].

Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol. 2017 Aug;140(2):335-48. doi: 10.1016/j.jaci.2017.06.003, PMID 28780941.

Minutello K, Gupta V. Cromolyn sodium. StatPearls. 2022. Available from: https://pubmed.ncbi.nlm.nih.gov/books/NBK557473.

Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmol. 2009;87(5):549-54. doi: 10.1111/j.1755-3768.2008.01265.x, PMID 18631332. Available from: https://www.researchgate.net/publication/51405973_Efficacy_of_olopatadine_HCI_01_ketotifen_fumarate_0025_epinastine_HCI_005_emedastine_005_and_fluorometholone_acetate_01_ophthalmic_solutions_for_seasonal_allergic_conjunctivitis_A_placebo-controlled_e.

PubChem. Fluorometholone. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/9878. [Last accessed on 25 Jan 2023]

Ketorolac tromethamine 0.4% as a treatment for allergic conjuctivitis-PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/18433352. [Last accessed on 25 Jan 2023]

Celik T, Türkoglu EB. Comparative evaluation of olopatadine 0.01% combined fluorometholone 0.1% treatment versus olopatadine 0.01% combined ketorolac 0.4% treatment in patients with acute seasonal allergic conjunctivitis. Curr Eye Res. 2014;39(1):42-6. doi: 10.3109/02713683.2013.827213, PMID 24074291.

Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients-PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/22627057. [Last accessed on 25 Jan 2023]

Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis-PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/20531202. [Last accessed on 27 Jan 2023]

BAJD OD, Scheid T. Antiinflammatories in ocular allergy treatment. Available from: https://www.reviewofoptometry.com/article/anti-inflammatories-in-ocular-allergy-treatment. [Last accessed on 27 Jan 2023]

Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model-PubMed. Clin Ther. 2001;23(8):1272-80. doi: 10.1016/s0149-2918(01)80106-5, PMID 11558863.

Yaylali V, Demirlenk I, Tatlipinar S, Ozbay D, Esme A, Yildirim C. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis-PubMed. Acta Ophthalmol Scand. 2003;81(4):378-82. doi: 10.1034/j.1600-0420.2003.00079.x, PMID 12859265.

Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus Ketotifen Ophthalmic solutions: a double-masked, environmental study of patient preference-PubMed. Curr Med Res Opin. 2004;20(8):1167-73. doi: 10.1185/030079904125004321, PMID 15324519.

Fauquert JL, Jedrzejczak Czechowicz M, Rondon C, Calder V, Silva D, Kvenshagen BK. Conjunctival allergen provocation test: guidelines for daily practice. Allergy. 2017 Jan;72(1):43-54. doi: 10.1111/all.12986, PMID 27430124.

Allergic conjunctivitis: a comprehensive review of the literature-PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/23497516. [Last accessed on 27 Jan 2023]

Kari: updates in the treatment of ocular allergies-Google Scholar. Available from: https://scholar. google.com/scholar_lookup?journal=J.+Asthma+Allergyandtitle=Updates+in+the+treatment+of+ocular+allergiesandauthor=O.+Kariandauthor=K.M.+Saariandvolume=3andpublication_year=2010andpages=149-158andpmid=21437049anddoi=10.2147/JAA.S13705and. [Last accessed on 27 Jan 2023]

Alwadani S. Safety and efficacy of sodium cromoglycate-fluorometholone fixed combination eye drops in allergic conjunctivitis. Saudi J Ophthalmol. 2022;36(1):107-12. doi: 10.4103/sjopt.sjopt_208_21, PMID 35971498.

Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis-PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/26028608. [Last accessed on 27 Jan 2023]

Meena DRK, Gupta DML, Sharma DHP. A comparative study of olopatadine and ketorolac eye drop with ketorolac eye drop alone in seasonal allergic conjunctivitis. Int J Med Res Rev. 2017 Sep 30;5(9):829-39. doi: 10.17511/ijmrr.2017.i09.01.

Sandoval HP, Fernandez de Castro LE, Vroman DT, Solomon KD. A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery. Clin Ophthalmol. 2007 Dec;1(4):367-71, PMID 19668513.